Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 3, 2014, Pages 156-163

  Ma, Wanlong ^a   Diep, Kevin ^a   Fritsche, Herbert A ^b   Shore, Neal ^c   Albitar, Maher ^a  

^a NeoGenomics California   (United States)

^b Health Discovery Corporation   (United States)

^c Carolina Urologic Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CHAPERONIN 60; GAPDH PROTEIN; IMPDH2 PROTEIN; PCA3 PROTEIN; PDL1M5 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR MARKER; UAP1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC AND PROGNOSTIC SCORING SYSTEM; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; URINE; VERY ELDERLY; ALGORITHM; BLOOD; CANCER STAGING; EVALUATION STUDY; METHODOLOGY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR INVASION;

AGED; AGED, 80 AND OVER; ALGORITHMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84896756738     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0424     Document Type: Article

References (31)

1. Augustin H, Mayrhofer K, Pummer K, et al. (2013) Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 73:203-210.
2. Auprich M, Bjartell A, Chun FK, et al. (2011) Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 60:1045-1054.
3. Barry MJ (2001) Prostate-specific-Antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373-1377.
4. Carter HB, Partin AW, Walsh PC, et al. (2012) Gleason Score 6 adenocarcinoma: Should it be labeled as cancer?. J Clin Oncol 30:4294-4296.
5. Casadio V, Calistri D, Salvi S, et al. (2013) Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: A pilot study. Biomed Res Int 2013:270457.
6. Cooperberg MR, Simko JP, Cowan JE, et al. (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31:1428-1434.
7. Cuzick J, Swanson GP, Fisher G, et al. (2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 12:245-255.
8. De Kok JB, Verhaegh GW, Roelofs RW, et al. (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62:2695-2698.
9. Detchokul S, Frauman AG (2011) Recent developments in prostate cancer biomarker research: Therapeutic implications. Br J Clin Pharmacol 71:157-174.
10. Diamond E, Lee GY, Akhtar NH, et al. (2012) Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2:131-142.
11. Epstein JI, Allsbrook WC Jr, Amin MB, et al. (2006) Update on the Gleason grading system for prostate cancer: Results of an international consensus conference of urologic pathologists. Adv Anat Pathol 13:57-59.
12. Guyon I, Fritsche H, Choppa P, et al. (2009) A four-gene expression signature for prostate cancer cells consisting of UAP1, PDLIM5, IMPDH2, and HSPD1. UroToday Int J 2:3834-3844.
13. Humphrey PA (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17:292-306.
14. Kobayashi Y, Absher DM, Gulzar ZG, et al. (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21:1017-1027.
15. Liong ML, Lim CR, Yang H, et al. (2012) Blood-based biomarkers of aggressive prostate cancer. PLoS One 7:e45802-e45808.
16. Liu Y, Hegde P, Zhang F, et al. (2012) Prostate cancer-A biomarker perspective. Front Endocrinol (Lausanne) 3:72-81.
17. Loeb S, Partin AW (2011) Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol 13:e191-e195.
18. Moyer VA, US Preventive Services Task Force (2012) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134.
19. Orsted DD, Bojesen SE (2013) The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 10:49-54.
20. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 162:293-306.
21. Prensner JR, Rubin MA, Wei JT, et al. (2012) Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med 4:127-138.rv3.
22. Rafi T, Sattar A, Asif N, et al. (2003) The comparison of percent free PSA with total PSA in the diagnosis of prostate cancer. JPMA 53-56.
23. Ribeiro da Silva MN, Tobias-Machado M, Lima-Pompeo AC, et al. (2012) Prostate cancer: Promising biomarkers related to aggressive disease. Actas Urol Esp 36:484-490.
24. Salami SS, Schmidt F, Laxman B, et al. (2013) Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 31:566-571.
25. Shariat SF, Scherr DS, Gupta A, et al. (2011) Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 64:681-694.
26. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
27. St John J, Powell K, Conley-Lacomb MK, et al. (2012) TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther 4:94-101.
28. Thompson IM, Pauler DK, Goodman PJ, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2239-2246
29. Vickers AJ, Brewster SF (2012) PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol 5:162-168.
30. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975-1986.
31. Zhaohui C, Jun Z, Jianmin W, et al. (2002) The application of complex PSA and its relative indexes in the detection of prostate cancer. Chinese-German J Clin Oncol 1:233-237.